We are live on ! Find out more
T

TOBAM Portfolio holdings

AUM $412M
1-Year Est. Return 18.33%
This Fund
S&P 500
This Quarter Est. Return
+7.64%
1 Year Est. Return
+18.33%
3 Year Est. Return
+56.05%
5 Year Est. Return
+49%
10 Year Est. Return
+255.15%
AUM
$2.5B
AUM Growth
+$144M
Cap. Flow
+$16.9M
Cap. Flow %
0.68%
Top 10 Hldgs %
23.95%
Holding
453
New
26
Increased
85
Reduced
124
Closed
20

Top Buys

Rank Stock Value
1
LLY icon
Eli Lilly
LLY
+$23M
2
NVAX icon
Novavax
NVAX
+$18.4M
3
IQ icon
iQIYI
IQ
+$17.4M
4
CBOE icon
Cboe Global Markets
CBOE
+$17M
5
NFLX icon
Netflix
NFLX
+$16.8M

Top Sells

Rank Stock Value
1
SRPT icon
Sarepta Therapeutics
SRPT
+$27.7M
2
ROKU icon
Roku
ROKU
+$20.6M
3
SPG icon
Simon Property Group
SPG
+$16.5M
4
NIO icon
NIO
NIO
+$15.7M
5
MRNA icon
Moderna
MRNA
+$13.5M

Sector Composition

Rank Sector Weight
1 Consumer Staples 21.66%
2 Healthcare 21.01%
3 Consumer Discretionary 11.38%
4 Communication Services 10.4%
5 Materials 8.2%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
NUAN
451
DELISTED
Nuance Communications, Inc.
NUAN
-951
Closed -$42K
KSU
452
DELISTED
Kansas City Southern
KSU
-322
Closed -$85K
VER
453
DELISTED
VEREIT, Inc.
VER
-887
Closed -$34K

Similar funds

TOBAM's Q2 2021 Portfolio in Review

As of Q2 2021, TOBAM held 453 positions worth $2.5B, up 6.1% from $2.35B the previous quarter. Its ten largest holdings account for 24% of the portfolio.

TOBAM's Q2 2021 filing shows 26 new, 85 increased, 124 reduced and 20 closed positions. Its largest new stake was GFL Environmental: 313,947 shares worth $10M. The largest sale was Sarepta Therapeutics, an estimated $27.7M.

By sector, the portfolio is most concentrated in Consumer Staples at 22% of assets, down from 22% a quarter earlier, followed by Healthcare and Consumer Discretionary.

  • TOBAM's largest Q2 2021 buy was GFL Environmental: 313,947 shares worth $10M.
  • TOBAM added most to Eli Lilly in Q2 2021, an estimated $23M increase.
  • TOBAM's biggest Q2 2021 reduction was Roku, cutting an estimated $20.6M.
  • TOBAM fully exited Sarepta Therapeutics in Q2 2021, selling an estimated $27.7M.
  • TOBAM's ten largest holdings make up 24% of its $2.5B portfolio in Q2 2021.
  • TOBAM opened 26 new positions and closed 20 in Q2 2021.
  • TOBAM's portfolio value rose 6.1% quarter-over-quarter to $2.5B.

Based on TOBAM's 13F filing for Q2 2021, filed 11 Aug 2021.